Immix Biopharma, Inc. (ticker: IMMX) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of IMMX's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. IMMX reported $20.00M in revenue and -$10.09M for the period ending 2022-12-08, with operating cash flow of -$9.83M. Cash and equivalents stood at $79.25M (up 397.8% year-over-year). Total assets of $95.82M exceed total liabilities of $11.45M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
IMMX Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Immix Biopharma, Inc. (IMMX) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.